Ionis Pharmaceuticals Q3 2026 Earnings Date & Estimates

Ionis Pharmaceuticals (NASDAQ:IONS) is a biotechnology company focused on discovering and developing medicines using antisense technology. Its platform is designed to selectively target RNA and regulate the production of disease-related proteins. The company develops therapies for neurological, cardiovascular and metabolic, and rare diseases.

Ionis has developed and commercialized medicines both independently and through collaborations with larger pharmaceutical companies. Its marketed or partnered products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Wainua (eplontersen) for hereditary transthyretin amyloidosis, and Tryngolza (olezarsen) for familial chylomicronemia syndrome. The company also maintains a pipeline of investigational antisense medicines, including candidates for neurological and cardiometabolic conditions.

Founded in 1989, Ionis is headquartered in Carlsbad, California, and serves patients internationally through its own commercial activities and partnerships. The company has collaborated with organizations including Biogen and AstraZeneca. Brett P. Monia serves as chief executive officer and has held senior leadership roles at Ionis for many years.